Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

argenx NV ADR

ARGX
Current price
370.68 USD +10.31 USD (+2.86%)
Last closed 376.26 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 22 609 557 504 USD
Yield for 12 month -3.45 %
1Y
3Y
5Y
10Y
15Y
ARGX
21.11.2021 - 28.11.2021

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. Address: Laarderhoogtweg 25, Amsterdam, Netherlands, 1101EB

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

478.76 USD

P/E ratio

Dividend Yield

Current Year

+1 226 316 000 USD

Last Year

+410 746 000 USD

Current Quarter

+407 434 794 USD

Last Quarter

+329 789 000 USD

Current Year

+1 108 481 000 USD

Last Year

+381 315 000 USD

Current Quarter

+264 416 956 USD

Last Quarter

+293 790 000 USD

Key Figures ARGX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -316 815 008 USD
Operating Margin TTM -32.75 %
PE Ratio
Return On Assets TTM -6.85 %
PEG Ratio
Return On Equity TTM -8.54 %
Wall Street Target Price 478.76 USD
Revenue TTM 1 268 594 048 USD
Book Value 69.22 USD
Revenue Per Share TTM 0.89 USD
Dividend Share
Quarterly Revenue Growth YOY 134.9 %
Dividend Yield
Gross Profit TTM -251 786 000 USD
Earnings Share -5.14 USD
Diluted Eps TTM -5.14 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -23.26 %

Dividend Analytics ARGX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ARGX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ARGX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 16.1275
Price Sales TTM 17.8225
Enterprise Value EBITDA -102.8545
Price Book MRQ 5.5555

Financials ARGX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ARGX

For 52 weeks

327.73 USD 550.76 USD
50 Day MA 390.14 USD
Shares Short Prior Month 1 343 035
200 Day MA 444.25 USD
Short Ratio 4.68
Shares Short 1 204 315
Short Percent 1.93 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds


M

MDAXEX

208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics

Metals


Gold

2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics